Brain Metastases Diagnosis
Brain Metastases Diagnosis
In most patients the diagnosis is made on imaging rather than on tissue, because the cancer is already known and the question is what has appeared in the brain. Contrast-enhanced MRI is the standard, and it answers the questions that decide treatment: how many deposits there are, how large they are and where they sit. What testing adds is the molecular profile of the cancer, which is what determines whether a drug that reaches the brain is available.
Imaging: what MRI shows that CT does not
Contrast-enhanced MRI is the investigation of choice, and the reason is practical rather than theoretical — it changes what can be offered:
- It finds more deposits. Small deposits, and those lying close to bone or in the back of the brain, are easily missed on CT. Since the number of deposits decides whether focused radiotherapy is possible, undercounting them changes the recommendation.
- It shows the deposit and the swelling around it separately. This is what allows treatment to be aimed at the deposit while the swelling is managed medically.
- It describes where the deposit sits relative to critical tissue — the areas controlling movement, speech and vision — which determines whether an operation is safe and how radiotherapy must be shaped.
- CT still has a place — in an emergency, when MRI cannot be performed, or when bone and bleeding need to be seen quickly.
The comparison that really decides treatment is made on the images themselves rather than while reading the report. That is why it is worth bringing the images and not only the report: a report describes this examination, whereas the comparison against the previous one is what decides what happens next.
When tissue is taken from the brain
Most deposits are treated without a biopsy, because the cancer elsewhere is known and the imaging appearances are characteristic. There are specific situations in which tissue is needed:
- When no original cancer has been identified. A deposit found before the source is known has to be examined, both to establish what the cancer is and to test the markers that decide treatment.
- When the appearance is not typical. A single deposit in a patient whose cancer is in remission, an unusual pattern, or a lesion in an unusual site may require confirmation that it is a deposit rather than a tumour that began in the brain.
- When a change on the scan may not be the cancer. After radiotherapy, an enlarging area may be tumour or may be the effect of treatment on the tissue, and where the distinction cannot be made by imaging, a biopsy settles it.
- When it is removed as treatment anyway. A deposit that is being operated on because of pressure or because of its site provides tissue at the same time, and testing it may reveal markers that the original tumour did not show.
The distinction worth making is that a biopsy here is a diagnostic procedure rather than a treatment, that it carries a small risk of its own, and that it is therefore used only where the answer really would change the plan. If the deposit is going to be treated with focused radiotherapy and the markers are already known from the original tumour, a biopsy usually adds little.
When the primary cancer is not known
In a minority of patients, a deposit in the brain is found before the cancer that produced it has been identified. The search for the source then becomes part of diagnosis, and it follows a defined order:
- Review of the imaging already performed — a scan of the chest is frequently the study that identifies the source, since lung cancer is the commonest origin of these deposits.
- Cross-sectional imaging of the chest, abdomen and pelvis, or a whole-body imaging study, to identify a tumour elsewhere and to record how far the disease has spread.
- Biopsy of the brain deposit where no accessible site exists, or where the deposit is being removed in any case.
- Pathology that points to the source. The appearance of the tissue and its protein markers often indicate the organ of origin even when imaging has not found a tumour, and molecular testing of the deposit's tissue is becoming more informative.
It is worth asking how far the search should go. The answer depends on whether the result would change treatment: finding an actionable molecular target, or a tumour for which an effective drug exists, justifies the investigation, whereas a prolonged search in a patient whose disease is already widespread and whose functional state is poor may not. That is a judgement made jointly by the team and the patient, and asking directly what a given test is meant to answer is an entirely reasonable question.
The molecular report, and why it decides treatment
In this condition, the molecular profile of the cancer is not supplementary information — it is frequently the finding that determines the first treatment, because several drugs selected by marker reach the brain in useful concentrations:
- Lung cancer — EGFR, ALK, ROS1 and related drivers, and PD-L1 status. Several agents that act on these targets are effective within the nervous system, so a deposit may reasonably be treated with a tablet before or instead of radiotherapy.
- Breast cancer — HER2 status and hormone-receptor status. HER2-directed treatment has changed what is achievable for deposits from HER2-positive disease.
- Melanoma — BRAF mutation, which makes BRAF and MEK inhibitors relevant, and PD-L1 status, since immunotherapy is effective in this cancer.
- Colorectal and other cancers — RAS and RAF status, mismatch-repair or MSI status, and any marker for which a drug with activity in the brain exists.
Two consequences are worth stating plainly. First, a treatment plan that describes the cancer but not its markers may have left the most effective option out of consideration, and asking for the molecular report is a reasonable place to start. Second, results can differ between the original tumour and a deposit, so where a marker is negative on old tissue and a targeted drug would otherwise be relevant, retesting may be worthwhile. Both points are matters of fact rather than of opinion, and both can be put to the treating team directly.
How the extent of the disease is recorded
There is no staging system with numbers for this condition. What is recorded instead is a set of features, and each of them contributes to what is recommended:
- The number of deposits, counted on contrast-enhanced MRI — the finding that decides whether focused radiotherapy is possible and whether whole-brain treatment should be considered.
- Whether the fluid spaces are involved, which is assessed when symptoms or imaging suggest it, and which changes the treatment substantially.
- The state of the disease outside the brain, since control of the cancer elsewhere is one of the factors that determines how much treatment the brain can reasonably be given.
- Function and neurological state, recorded at the outset and reviewed throughout, because it determines what can be tolerated and what can be recovered.
- The molecular subtype of the cancer, which together with the above forms the basis of the formal prognostic assessment used in this disease.
Formal prognostic scores in this condition combine the patient's age, functional status, the number of deposits, the extent of disease elsewhere and the molecular subtype of the cancer. What those factors are matters, because they are what a recommendation is built on and what can be discussed; what they are not is a prediction to be applied to an individual patient. The useful question is therefore not "what is my score" but "which of these factors can be changed, and what would changing them make possible".
What the diagnosis should establish
By the end of the assessment, these are the points that should have been answered, and asking for them by name is a reasonable way to check that nothing has been left out:
- What the cancer is, and when it was diagnosed — since the treatment of the deposit follows the behaviour and the sensitivities of the original cancer.
- What markers it carries, tested on the tissue available, and whether retesting is worth doing.
- How many deposits there are, and where they sit relative to the areas that control movement, speech, vision and the flow of fluid.
- Whether the fluid spaces are involved, and how that was assessed.
- What the disease elsewhere is doing, and what treatment it is currently receiving.
- What the options are, in what order, and what would cause that order to change — which is the part of the discussion worth writing down.
The reason to insist on all six is that this condition is managed as a whole rather than site by site. A plan that treats the deposit in the brain while leaving the question of the markers unasked, or that treats the cancer systemically while ignoring a deposit causing pressure, is a plan with a gap in it. The gap is usually found not by further tests but by a team that includes both the specialists in the nervous system and those managing the cancer, which is why the assessment is worth arranging in a setting where both are available together.